Description：Immunoassay for quantitative estimation of Degarelix in human serum, plasma and cell culture supernatant.
Degarelix is used for the treatment of advanced prostate cancer.
Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone （GnRH）receptors in the pituitary gland and blocks interaction with GnRH.
This antagonism reduces luteinizing hormone （LH） and follicle-stimulating hormone （FSH） which ultimately causes testosterone suppression.
Reduction in testosterone is important in treating men with advanced prostate cancer.
FDA approved the same as "Firmagon" in December 2008.
About the kit：
- Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity.
- Recovery rates are between 85 - 115％
- Ready to use with a standard protocol with break-apart pre-coated wells
- Validated as per US FDA guidelines for Bioassays
- Optimized for matrix effects to ensure higher sensitivity.
- Shelf life： 1 year
The ELISA is a competitive immunoassay for the determination of Degarelix.
A constant concentration of Degarelix coated on the microplate and varying concentration of standard or sample will compete for binding to gonadotropin-releasing hormone （GnRH） receptor.
Detection antibody against GnRH conjugated to HRP is added to form a complex.
The complex will produce a soluble colored product on substrate addition.
The enzyme reaction is stopped by dispensing of Stop Solution into the wells.
The optical density （OD） of the solution at 450 nm is inversely proportional to the amount of bound Degarelix present in standards or samples.
